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Abstract 
The benefit of pharmacokinetic assessment of sunitinib remains unknown. We 
reported that patients with total sunitinib (sunitinib + its active metabolite 
SU12662) ≥100 ng/mL showed high incidence of Grade ≥3 toxicities and worsening 
clinical outcomes. Thus, pharmacokinetic assessment of sunitinib could be helpful 
for dose optimization. 
Background 
Sunitinib has been approved for the treatment of metastatic renal cell carcinoma (RCC). 
Sunitinib pharmacokinetics shows a large inter-patient variability. 
 Patients and Methods 
A retrospective, observational clinical study of 21 patients with RCC was performed. 
Sunitinib was administered for 4 weeks of a 6-week cycle for the first cycle. We 
evaluated the association of sunitinib-induced toxicities and clinical outcomes with the 
trough total sunitinib concentration in a steady state during the first cycle.   
Results 
The median total sunitinib concentration was 91.8 ng/mL (range 49.8-205 ng/mL). 
There was an association between total sunitinib concentration and the severity of 
thrombocytopenia, anorexia and fatigue. Patients with ≥100 ng/mL total sunitinib (n=8), 
5 
 
as compared with patients with <100 ng/mL (n=13), had a higher incidence of Grade ≥3 
toxicities (75% vs. 23%). Patients with <100 ng/mL total sunitinib had significantly 
longer time to treatment failure (TTF), progression-free survival time (PFS) than 
patients with ≥100 ng/mL (median TTF 590 vs. 71 days, P=0.04; median PFS 748 vs. 
238 days, P=0.02)  
Conclusions 
This study suggests that therapeutic drug monitoring of sunitinib could be useful for 
avoiding severe toxicities. Dose reduction may be needed, especially when the total 
sunitinib concentration is ≥100 ng/mL, to avoid unnecessary early discontinuation of 
treatment.  
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Introduction 
Sunitinib is an oral multikinase inhibitor that targets vascular endothelial growth factor 
receptor, platelet-derived growth factor receptors, and stem cell factor receptor. It has 
been approved for the treatment of advanced and/or metastatic renal cell carcinoma 
(RCC) as the first-line treatment.
1
 Sunitinib frequently induces severe toxicities such as 
thrombocytopenia, anorexia, fatigue, hand-foot syndrome (HFS), and bleeding event.
1
 
In addition, sunitinib induces rare, but potentially life-threatening events such as 
intestinal perforation, interstitial lung disease, and would healing complication.
2-4
 
Because these toxicities are difficult to handle and anticipate, dose reduction or 
discontinuation is generally carried out in daily clinical settings. As a consequence, 
physicians must closely monitor all patients who have started sunitinib treatment. 
Against this background, a predictive marker for preventing severe sunitinib-induced 
toxicities is needed.  
Therapeutic drug monitoring (TDM) has been widely used to improve efficacy and to 
avoid adverse events for various drugs.
5
 At present, although many anticancer agents 
show large interindividual variability for pharmacokinetics (PK), TDM has not been 
routinely used in chemotherapy management. Recently, clinical studies have reported 
that trough imatinib plasma levels are associated with both cytogenetic and molecular 
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response in chronic myeloid leukemia.
6,7
 Regarding toxicity, several studies have 
demonstrated that the area under the curve (AUC) of erlotinib was associated with the 
occurrence of skin toxicity.
8,9
 Implementation of TDM may contribute to optimal dose 
adjustment for other oral molecular-targeted anticancer agents including sunitinib. In 
fact, considerable interindividual differences in sunitinib PK have been observed.
10
 The 
reason for severe toxicity in some patients may be the interindividual variation in serum 
levels of sunitinib. However, a pharmacokinetic (PK) approach to evaluate the side 
effects of sunitinib is lacking. Furthermore, information on the associations between 
sunitinib PK and clinical outcomes and pharmacogenomic factors is insufficient.  
Sunitinib is primarily metabolized by cytochrome P450 (CYP) 3A4 to the equally 
active SU12662. SU12662 is further metabolized to inactive moieties by CYP3A4.
11
 
Previous studies have reported that sunitinib is a substrate for ATP-binding cassette 
transporters, ABCG2
12
 and ABCB1,
13
 which affect the intestinal absorption and biliary 
excretion of various drug substrates.
14
 In this study, we evaluated polymorphism in 
CYP3A5 (6986G>A), ABCG2 (421C>A, 34G>A, 1143C>T), and ABCB1 (1236C>T, 
2677G>T/A, 3435C>T) (Table 1). Regarding the ABCB1 variants, we assessed ABCB1 
1236-2677-3435 TTT haplotype, which are associated with low expression.
15
 
In the present study, the primary aim was to evaluate the association of sunitinib 
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concentration with sunitinib-induced toxicity in patients with RCC. The secondary aim 
was to estimate the association of sunitinib PK with clinical outcome and genetic 
polymorphisms related to the PK of sunitinib. 
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Patients and Methods 
Patients 
This was a two-institution study conducted at Shiga University of Medical Science 
Hospital and Shiga Medical Center for Adults. Twenty-one Japanese RCC patients 
treated with sunitinib were enrolled between September 2010 and March 2013. 
Eligibility criteria included histological confirmation and Eastern Cooperative 
Oncology Group (ECOG) performance status of 0, 1, or 2. This study was approved by 
the relevant institutional review boards.  
 
Treatment plan 
Sunitinib was administered at a dose of 50 mg, 37.5 mg, or 25 mg daily based on the 
treating physicians’ recommendation for 4 weeks of a 6-week cycle for the first cycle. 
Subsequently, dose reduction or discontinuation was adjusted based on adverse events 
or disease progression.  
 
Assessment of safety and efficacy  
All adverse events were graded according to the Common Toxicity Criteria for 
Adverse Effects v4.0. The worst clinically significant treatment-associated toxicities 
11 
 
were analyzed. We also examined major bleeding events, as previously defined.
16
 The 
best tumor response was assessed using the Response Evaluation Criteria in Solid 
Tumors (RECIST version 1.1).
17
 Time for assessment was dictated by the individual 
institutional policies.  
 
Assessment of serum level of sunitinib 
After informed consent had been obtained from the patients, blood samples were 
collected before administration at a steady state (days 10-28) after the initiation of 
sunitinib treatment during the first cycle. We retrospectively evaluated the serum 
concentrations of sunitinib and its major metabolite, SU12662, using stored blood 
samples. Blood samples were drawn into a sterilized vacuum tube for separation just 
before sunitinib administration. All samples were centrifuged at 1700 g and 4˚C for 10 
minutes, and serum was separated and stored at -20˚C.  
Sunitinib and SU12662 were measured by high-performance liquid chromatography, 
as previously described.
18
 The observed intraday and interday assay imprecision and 
inaccuracy were <10%. The lower limits of quantification of sunitinib and SU12662 
were 10 ng/mL and 5 ng/mL, respectively.  
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Single-nucleotide polymorphisms (SNPs) related to the PK of sunitinib 
Genomic DNA was extracted from the blood using DNA Extract All Reagents 
(Applied Biosystems, Foster City, CA, USA). Subsequently, genotyping was performed 
using TaqMan
®
 SNP genotyping assay (Applied Biosystems) in a Step One Plus Real 
time PCR system (Applied Biosystems). Amplification conditions were 95˚C for 20 s, 
40 cycles of 95˚C for 3 s, and 60˚C for 20 s.  
 
Statistical analysis 
Descriptive data are expressed as means ± SD or median. Continuous variables were 
compared using Mann-Whitney U-test. Categorical variable were compared by 
Chi-square test or Fisher’s exact test. The correlation between serum concentration of 
sunitinib and blood cell count was determined using Spearman’s test. The correlation 
between the severity of non-hematological toxicities and total sunitinib concentration 
was evaluated by the Jonckheere-Terpsta test. Time-to-event variables were estimated 
using the Kaplan-Meier method and log rank test. Time to treatment failure (TTF) was 
defined as the period from the first day of sunitinib treatment until cessation of sunitinib 
treatment due to any cause. Progression-free survival (PFS) was defined from the date 
of treatment initiation to the date of objective tumor progression or death. Overall 
13 
 
survival (OS) was defined from the date of sunitinib initiation until the date of death. 
Patients lost to follow-up were censored at the time of last contact. The cut-off date for 
this analysis was March 31, 2014. Median follow-up was 482 days (range 48-1001). 
Allele frequencies were tested for Hardy-Weinberg equilibrium using the Chi-square 
test. Correlations between genotypes related to sunitinib PK and the dose-adjusted total 
sunitinib concentration were evaluated by one-way analysis of variance and Tukey test. 
All comparison tests were two-sided. A p-value <0.05 was considered to be statistically 
significant. All statistical analyses were performed using SPSS ІІ v. 22.0.   
14 
 
Results 
Patient characteristics 
Twenty-one patients were treated with sunitinib. Baseline characteristics are shown in 
Table 2. The median age was 68 years (range 56-83), and 18 patients (85.7%) had clear 
cell histology. Patients were started on sunitinib at doses of 50 mg (n=11), 37.5 mg 
(n=5), and 25 mg (n=5) daily. The median trough total sunitinib concentration was 91.8 
ng/mL (range 49.8-205). To evaluate drug exposure and the safety/efficacy relationship, 
we grouped the population into patients with “low” exposure and “high” exposure. In 
this study, we used a total sunitinib concentration of 100 ng/mL as the cut-off value, 
which was previously reported as being associated with most patients experiencing 
dose-limiting toxicity.
19
 Toxicity and clinical outcome due to sunitinib were compared 
between the two groups.  
 
Association of toxicities with total sunitinib concentration 
In the first cycle of sunitinib, a clear inverse correlation was found between the total 
sunitinib concentration and the blood platelet count at nadir (r=-0.53, P=0.01), but not 
hemoglobin level count (r=0.04, P=0.86) or leukocyte count (r=0.14, P=0.55) (Fig. 1).  
A positive trend was observed between total sunitinib concentration and higher-grade 
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toxicity of anorexia and fatigue (Fig. 2a, b). In addition, total sunitinib concentration 
was not correlated with the severities of HFS and hypertension (Fig. 2c, d). The mean 
total sunitinib concentration was greater in patients with bleeding events (n=10) than in 
those without them (n=11) (116±43.4 vs. 77.2±22.2 ng/mL, respectively, P=0.13) (Fig. 
2e). 
 
Association of dose reduction or discontinuation of sunitinib with total sunitinib 
concentration 
In the low-exposure group (total sunitinib <100 ng/mL, n=13), three patients (23.1%) 
experienced grade 3 thrombocytopenia during the first cycle. Dose reductions from 50 
mg to 37.5 mg were performed in 2 patients, which resulted in attenuation of the 
thrombocytopenia. In this group, the toxicities of sunitinib therapy were mild (grade ≤1 
toxicities), except for the thrombocytopenia, and controllable. The final reasons for 
sunitinib discontinuation were disease progression (n=5), interstitial lung disease (n=2), 
grade 3 anorexia (n=2), and grade 3 pancreatitis (n=1).  
In the high-exposure group (total sunitinib ≥100 ng/mL, n=8), six (75%) of the 8 
patients experienced Grade ≥3 toxicities during the first cycle. Owing to its toxicities, 
dose reductions from 50 mg to 37.5 mg were performed in 5 patients. In 2 patients, the 
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dose was reduced from 50 mg to 25 mg. In this group, three patients, who were 
managed as outpatients, were hospitalized due to grade 3 anorexia (n=2) and intestinal 
perforation (n=1). Additionally, one patient experienced protracted wound healing for 
the first cycle. As a consequence, sunitinib was discontinued in 7 patients who 
experienced grade 3 anorexia (n=3), grade 3 fatigue (n=3), and intestinal perforation 
(n=1). The patient who experienced intestinal perforation was started on sunitinib at 50 
mg daily for 4 weeks of a 6-week cycle. This patient needed a dose reduction to 37.5 
mg after 1 cycle of sunitinib because of grade 3 thrombocytopenia. Six days after 
discontinuation of the second cycle of sunitinib, he presented with abdominal pain and 
muscle guarding. Computed tomography showed free air in the upper abdomen. 
Emergency laparotomy revealed localized perforation of the sigmoid colon. Resection 
of the sigmoid colon and colostomy were performed, and he recovered within 14 days. 
As shown in Figure 3, serum total sunitinib concentration was 205 ng/mL on day 16 of 
the first cycle. Serum total sunitinib concentrations of the second cycle ranged from 90 
to 160 ng/mL.  
 
Association of efficacy with total sunitinib concentration 
Eighteen (85.7%) of the 21 patients were included in the analysis of efficacy end 
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points. Waterfall plot of the greatest percentage changes from baseline in the sum of the 
longest diameters of target lesions according to a total sunitinib concentration of ≥100 
ng/mL, or <100 mg/mL are displayed in Figure 4. 
In the low-exposure group (total sunitinib <100 ng/mL, n=13), partial responses 
determined by RECIST were achieved in 3 patients (23.1%). Stable disease was 
observed in 8 patients (61.5%). In one patient, the efficacy could not be confirmed due 
to transfer to another hospital. One patient was not assessable due to early unacceptable 
toxicity before the first assessment.  
In the high-exposure group (total sunitinib ≥100 ng/mL, n=8), the best response of 
stable disease was observed in 7 patients (87.5%). One patient was not assessable due to 
early unacceptable toxicity before the first assessment.  
 
Association of TTF, PFS, and OS with total sunitinib concentration 
The median TTF, PFS, and OS were 163 days (95% confidence interval [CI], 9.12- 
317), 590 days (95% CI, 58.3-1122), and 939 days (95% CI, 585-1293), respectively. 
Additionally, a sub-group analysis of TTF, PFS, and OS was performed using total 
sunitinib concentration for the first cycle. 
The patients with <100 ng/mL total sunitinib (n=13) had significantly longer TTF than 
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patients with ≥100 ng/mL (n=8) (median 590 vs. 71 days, P=0.04) (Fig. 5a). Patients 
with <100 ng/mL total sunitinib had significantly longer PFS than patients with ≥100 
ng/mL (median 748 vs. 238 days, P=0.02) (Fig. 5b). Patients with <100 ng/mL total 
sunitinib showed only a tendency for significantly longer OS than patients with ≥100 
ng/mL (median 939 vs. 570 days, P=0.07) (Fig. 5c). 
 
Association of total sunitinib concentration with SNPs related to the PK of sunitinib 
 Pharmacogenomic data were available for 21 patients. The allele frequencies of 
polymorphism in ABCG2, ABCB1, and CYP3A5 are shown in Table 3. These SNPs 
were in Hardy-Weinberg equilibrium (P>0.05), except for the CYP3A5 (6986G>A). 
However, the observed deviation was small with P=0.01 for CYP3A5 (6986G>A). As 
shown in Fig. 6, no statistically significant associations between SNPs related to the PK 
of sunitinib and total sunitinib dose-adjusted concentration were observed.  
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Discussion 
 Despite the excellent efficacy of sunitinib, its severe toxicity is becoming a central 
issue in the treatment of RCC using it. Identifying a predictive marker of sunitinib 
toxicity is important to improve sunitinib therapy management. A previous report 
indicated that one RCC patient showed severe adverse events such as grade 3 
hypertension, grade 3 facial acne, and grade 3 elevation of amylase, and had 
maximum concentration and AUC of sunitinib that were 2.5-fold higher than those of 
four other patients with similar clinical characteristics.
12
 High exposure to sunitinib may 
be one of the reasons for the severe toxicities induced by it. In the present study, we 
showed that some patients with ≥100 ng/mL total sunitinib concentration were 
hospitalized due to its severe toxicities during outpatient therapy. Among them, one 
patient had to stop sunitinib permanently after 2 cycles due to intestinal perforation. Of 
interest is the fact that this patient had extremely high exposure to sunitinib (total trough 
sunitinib for the first cycle: 205 ng/mL). To identify the cause of the high concentration 
of sunitinib in this patient, we checked co-administered drugs. During the sunitinib 
therapy, this patient had taken azelnidipine, a CYP 3A4 inhibitor, as previously 
reported,
20
 in combination with it, which could have been related to the high 
concentration of sunitinib. 
20 
 
The development of TDM strategies should lead to the selection of an optimal regimen 
and dose for each individual patient based on drug PK. However, the usefulness of 
TDM of sunitinib is limited by the lack of established therapeutic ranges. A previous 
meta-analysis of metastatic RCC studies indicated that increased serum AUC to 
sunitinib and SU12662 is associated with improved treatment outcomes and some 
adverse effects.
21
 Although severe toxicity of sunitinib is becoming a central issue in the 
treatment of RCC using it, a threshold for the toxicity of sunitinib treatment has not 
been defined. A recent study demonstrated that total trough sunitinib concentration were 
highly correlated with its AUC0-24h.
22
 Therefore, we consider that total sunitinib trough 
concentration is a valid PK parameter for its toxicity. In a phase І study, a case 
presentation of three patients indicated that total sunitinib trough concentration ≥ 100 
ng/mL may be associated with dose-limiting toxicity.
19
 In agreement with this study, we 
showed that most of the patients with total trough sunitinib ≥ 100 ng/mL experienced 
unacceptable toxicities. This could have led to early treatment discontinuation or 
delayed administration, which resulted in suboptimal efficacy of sunitinib. In fact, in the 
present study, the high-exposure group (≥100 ng/mL total sunitinib) showed a shorter 
TTF and PFS. These observations suggest that ≥100 ng/mL total sunitinib trough 
concentration may be a limiting factor leading to treatment discontinuation. 
21 
 
Preclinical studies have demonstrated that sunitinib is effective at total plasma 
concentrations of 50-100 ng/ml.
23
 In a clinical trial, Faivre et al.
19
 reported that the total 
sunitinib concentration obtained with a dose of 50 mg daily ranged from 50 to 100 
ng/ml. Uemura et al.
24
 also reported that sunitinib was effective at plasma 
concentrations ≥50 ng/ml in patients with metastatic RCC. In the present study, 95.2% 
of patients (20/21) exceeded 50 ng/mL total sunitinib, and these patients showed either a 
partial response or stable disease as the best response. Additionally, considering 
sunitinib toxicity, when targeting ≥100 ng/mL total sunitinib, it is difficult to maintain 
sunitinib treatment for a long period of time. Therefore, the target range could be a total 
sunitinib trough concentration of 50-100 ng/mL during sunitinib therapy.  
In this study, total sunitinib concentration was significantly associated with TTP and 
PFS. However, it was not significantly associated with OS. This discrepancy may partly 
contribute to the availability of sequential administration of target therapy after the 
discontinuation of sunitinib treatment. Guidelines recommend everolimus
25
 and 
axitinib
26
 for patients with advanced RCC refractory to prior systemic therapy, including 
sunitinib. In the present study, nine (42.9%) of 21 patients were subsequently treated 
with target therapy, including everolimus (n=4) and axitinib (n=5), after sunitinib 
discontinuation. These observations suggest that additional treatment could be 
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beneficial for patients who discontinued sunitinib due to severe toxicity or progressive 
disease. 
To identify the cause of the large inter-patient variability in sunitinib exposure in this 
study, we checked genetic polymorphism related to sunitinib PK. Previous preclinical 
and clinical studies reported that functional loss of ABCG2 was associated with 
increased sunitinib exposure.
12,27,28
 Another study reported that ABCG2 421C>A 
polymorphism may be mostly associated with the risk of sunitinib-related toxicity in 
mRCC patients.
29
 In disagreement with these studies, our data showed that 
polymorphism related to PK of sunitinib, including ABCG2, was not related to total 
sunitinib dose-adjusted concentration. A recent pharmacogenomic study on the PK of 
sunitinib indicated that none of the SNPs in candidate genes for the PK of sunitinib 
appeared to be significantly associated with the clearance of sunitinib and SU12662 in 
114 RCC patients treated with sunitinib.
30
 Phenotypes of the PK of sunitinib are 
multifactorial, and not only genetics but also drug-drug interactions, poor compliance, 
and environment could have an impact on sunitinib PK. Therefore, we need to perform 
prospective PK/pharmacogenomic study in RCC patients treated with sunitinib.  
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Conclusions 
The present study showed that several side effects of sunitinib were dose-dependent. 
Discontinuation occurred significantly more frequently in patients with total sunitinib 
trough concentration ≥100 ng/mL. Dose reduction may be needed, especially when the 
steady-state total sunitinib concentration is above 100 ng/mL. These findings suggest 
that therapeutic drug monitoring of sunitinib could be helpful for avoiding severe side 
effects, resulting in prolonged TTF and PFS upon sunitinib therapy. However, these 
results are debatable because the number of patients examined was very small and there 
were several differences in their back ground. In order to confirm these findings, large 
prospective PK studies should be performed.  
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Clinical practice point 
 Sunitinib, an oral multitargeted tyrosine inhibitor, has shown single-agent activity 
in patients with metastatic RCC. Sunitinib pharmacokinetics shows a large 
inter-patient variability. However, information on pharmacokinetic assessment of 
sunitinib is limited. 
 In this retrospective, observational study, we explored pharmacokinetic relationship 
with safety or efficacy of sunitinib in 21 patients with RCC. We found that the 
severity of thrombocytopenia, anorexia, and fatigue appeared to be dose-dependent. 
Patients with ≥100 ng/mL total sunitinib (n=8), as compared with patients with 
<100 ng/mL (n=13), had a higher incidence of Grade ≥3 toxicities (75% vs. 23%). 
Furthermore, we indicated that patients with <100 ng/mL total sunitinib had 
significantly longer TTF, PFS than patients with ≥100 ng/mL. 
 These findings suggested that TDM of sunitinib could be helpful for avoiding 
severe toxicities, resulting in prolonged TTF and PFS upon sunitinib therapy. 
However, this was a retrospective analysis of a small number of patients consisted 
of heterogeneous population. Therefore, these results need to be validated in a large 
prospective study.   
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Legends for figures 
 
Fig. 1  The relationship between total sunitinib concentration and hematological 
toxicity  
For the first cycle of sunitinib treatment, platelet count (a), hemoglobin level (b), and 
leukocyte count (c) at nadir were compared with trough total sunitinib (sunitinib + 
SU12662) at a steady state in 21 patients with renal cell carcinoma (RCC). Each symbol 
represents an individual patient. 
 
Fig. 2  The relationship between total sunitinib concentration and 
non-hematological toxicity  
For the first cycle of sunitinib treatment, anorexia (a), fatigue (b), hand-foot syndrome 
(c), hypertension (d), and bleeding event (e) were compared with trough total sunitinib 
at a steady state in 21 patients with RCC. All adverse events were graded using the 
Common Toxicity Criteria for Adverse Effects v4.0. Each symbol represents an 
individual patient.  
 
Fig.  3   A case of perforation of the sigmoid colon possibly related to high 
33 
 
exposure to sunitinib  
Serum concentrations of total sunitinib during sunitinib therapy in a patient who 
experienced intestinal perforation. Arrows indicate the occurrence of perforation of the 
sigmoid colon. Gray area shows the therapeutic range of sunitinib (50-100 ng/ml) 
(reference 23). 
 
Fig.  4  Waterfall plot of the greatest percentage change from baseline in the sum 
of the longest diameters of target lesions  
Open squares, patients with a total sunitinib concentration <100 ng/mL; closed squares, 
patients with a total sunitinib concentration ≥100 ng/mL. 
 
Fig. 5  Kaplan-Meier curve of time to treatment failure (TTF) (a), 
progression-free survival (PFS) (b), and overall survival (OS) (C) according to 
sunitinib exposure in patients with renal cell carcinoma  
Solid lines, patients with a total sunitinib concentration <100 ng/mL; dotted lines, 
patients with a total sunitinib concentration ≥100 ng/mL. Small closed diamond marks 
represent censored patients (end of follow-up).  
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Fig.  6  The relationship between total sunitinib concentration and SNPs related 
to the PK of sunitinib 
We examined the effect of genetic polymorphism in CYP3A5 (a), ABCG2 (b-d), and 
ABCB1 (e). C/D ratio represents total sunitinib dose-adjusted concentration.  
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Table 1  Selected SNPs related to sunitinib PK 
 
gene  SNPs  rs number  Region  
CYP3A5  CYP3A5 6986G>A  rs776746  Intron  
ABCG2  ABCG2 421C>A  rs2231142  Non-synonymous Q141K  
ABCG2  ABCG2 34G>A  rs2231137  Non-synonymous V12M  
ABCG2  ABCG2 1143C>T  rs2622604  Intron  
ABCB1  ABCB1 1236C>T  rs1128503  Synonymous G412G  
ABCB1  ABCB1 2677G>T/A  rs2032582  Non-synonymous A893S/T  
ABCB1  ABCB1 3435G>T  rs104642  Synonymous I1445I  
 
 
 
 
 
 
 
 
 
 
 
 
Table
Click here to download Table: Table.docx
2 
 
Table 2  Patient Characteristics 
Chracteristic total (n=21) total sunitinib concentration P 
  
<100 (n=13) ≥100 (n=8) 
 
Median Age (range), yr 68 (56-83) 68 (56-83) 70 (59-79) 0.92 
Gender (Male/Female) 17/4 10/3 7/1 0.50 
Median Weight (range), kg 56 (37-80) 56 (37-74) 50 (45-80) 0.33 
Median AST (range), IU/L 22 (9-86) 22 (9-59) 26 (19-86) 0.41 
Median ALT (range), IU/L 13 (6-104) 16 (7-59) 11 (6-104) 0.46 
Median eGFR (range), 
mL/min/1.73m
2
 
41.8 (6.2-80.4) 41.5 (6.2-80.4) 50.8 (30.3-76.7) 0.50 
Median sunitinib concentration 
(range), ng/mL 
64.6 (30.6-137) 49.8 (30.6-75.6) 108 (64.7-137) <0.01 
Median SU12662 concentration 
(range), ng/mL 
22.5 (12.4-68.5) 22.7 (12.4-43.7) 22.3 (13.0-68.5) 0.75 
Median total sunitinib 
concentration (range), ng/mL 
91.8 (49.8-205) 80.2 (49.8-93.5) 125 (106-205) <0.01 
Initial dose, n (%) 
    
50 mg 11 (52.4) 4 (30.8) 7 (87.5) 0.03 
37.5 mg 5 (23.8) 5 (38.4) 0  (0.0) 
 
25 mg 5 (23.8) 4 (30.8) 1 (12.5) 
 
Histology, n (%) 
    
  Clear cell 18 (85.7) 11 (84.6) 7 (87.5) 0.62 
  papillary 3 (14.3) 2 (15.4) 1(12.5) 
 
Prior treatment, n (%) 
    
  No 12 (57.1) 7 (53.8) 5 (62.5) 0.67 
  sorafenib 5 (23.8) 4 (30.8)     1 (12.5) 
 
  Immunotherapy 4 (19.2) 2 (15.4) 2 (25.0)  
 
ECOG performance status, n (%) 
    
0 16 (76.2) 10 (76.9) 6 (75.0) 0.93 
1 3 (14.3) 2 (15.4)  1 (12.5) 
 
2 2 (9.5) 1 (7.7) 1 (12.5) 
 
AST, aspartate aminotransferase;  ALT, aranine aminotransferase; eGFR, estimated glomerular 
filtration rate;  ECOG, Eastern Cooperative Oncology Group 
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Table 3   Polymorphism genotype and allele frequency 
Gene  SNPs  Patients  Homozygous 
wild-type  
Heterozygous  Homozygous 
variant 
Allele 
frequency  
CYP3A5  CYP3A5 6986G>A  21 13 4 4 0.286 
ABCG2  ABCG2 421C>A  21 11 8 2 0.286 
ABCG2  ABCG2 34G>A  21 15 5 1 0.167 
ABCG2  ABCG2 1143C>T  21 17 4 0 0.095 
ABCB1  ABCB1 1236C>T  21 2 6 13 0.761 
ABCB1  ABCB1 2677G>T/A  21 3 10 8 0.619 
ABCB1  ABCB1 3435G>T  21 4 11 6 0.547 
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